Can you take Pantoprazole in the morning and Famotidine at night?
By
Dr Natalia Marceli Stephanes (PhD)
Author bio
Dr Natália Marcéli Stephanes PhD is a Pharmacist with expertise in Drugs Administration and Toxicity; Discovery of New Drugs; Cancer Treatment; Biochemical Analyzes and Hematological Analyzes. She writes and reviews content on these topics.
Dr Natália Marcéli Stephanes’ Highlights:
- Pharmacist at the Department of Health of Santa Catarina State, Brazil
- PhD with a focus on oncology treatment
- Years of experience in commercial pharmacy
- Bachelor, Master and PhD degrees in Pharmacy at the Federal University of Santa Catarina
Professional Experience:
From her undergraduate studies to her Master’s and Doctorate degrees in Pharmacy, Dr Natália Marcéli Stephanes has participated in numerous scientific studies in the field of oncology and onco-hematology at the University Hospital of the Federal University of Santa Catarina, Brazil. Her research has focused on understanding the molecular and biochemical bases of malignant neoplasms and investigating safer and more effective therapeutic alternatives.
Dr Natália Marcéli Stephanes has also served as an assistant professor of haematology for undergraduate students at the Federal University of Santa Catarina. Additionally, she held the position of professor of Hospital Pharmacy at the Qualificar Technical School in Brazil, where she developed instructional materials for use in the Pharmacy Postgraduate Program at the Leonardo Da Vinci University Center.
In addition to her academic experiences, Dr Natália Marcéli Stephanes possesses a strong expertise in commercial pharmacy, with in-depth knowledge of medications, their routes of administration, desired effects, adverse effects, and toxicity.
Currently, Dr Natália Marcéli Stephanes works as a Pharmacist at the Health Department of Santa Catarina State, where her role entails providing pharmaceutical scientific consulting services to judges.
Education:
- 2016 Bachelor in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2018 Master in Pharmacy at the Federal University of Santa Catarina, Brazil
- 2023 PhD in Pharmacy at the Federal University of Santa Catarina, Brazil
The main publications of Dr Natália Marcéli Stephanes are:
Falchetti M ; Delgobo M, Zancanaro H, Almeida K, Das Neves RN, Dos Santos B, Stefanes NM, et al. Bishop Omics-based identification of an NRF2-related auranofin resistance signature in cancer: Insights into drug repurposing. Comput. Biol. Med [Internet]. 2023; 152:106347.
Feuser PM, Matos dos Santos PC, Cordeiro AP, Stefanes NM, Walter LO, Maioral MF, Santos-Silva MC, et al. Antineoplastic activity of free 4-nitrochalcone and encapsulated in poly(thioether-ester) nanoparticles obtained by thiol-ene polymerization in two human leukemia cell lines (Jurkat and K562). J Drug Deliv Sci Technol [Internet]. 2022; 67:102924.
Jacques AV, Stefanes NM, Walter LO, Perondi DM, Efe FL, Souza LFS, Sens L, et al. Synthesis of chalcones derived from 1-naphthylacetophenone and evaluation of their cytotoxic and apoptotic effects in acute leukemia cell lines. Bioorg. Chem [Internet]. 2021; 116:105315.
Duarte BF, Vieira DSC, Lisboa ML, Stefanes NM, Grando LJ, Santos-Silva MC. Características clínico-epidemiológicas de pacientes portadores de carcinoma de células escamosas de boca. Arquivos Catarinenses de Medicina. 2021; 50(2): 232–245.
Machado V, Jacques AV, Stefanes NM, Santos-Silva MC, Biavatti MW. Anti-leukemic activity of semisynthetic derivatives of Lupeol. Nat. Prod. Res. 2021; 35(22):4494-4501.
Bigolin A, Maioral MF, Stefanes NM, Mascarello A, Chiaradia-Delatorre LD, Nunes RJ, Yunes RA, et al. A novel sulfonamide derivative as a strong and selective apoptotic agent against hematological malignancies. Chem. Pap. 2020; 74:2965–2976.
Bigolin A, Maioral MF, Stefanes NM, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Cytotoxic mechanisms of primin, a natural quinone isolated from Eugenia hiemalis, on hematological cancer cell lines. Anticancer Drugs. 2020; 31(7):709-717.
Maioral MF, Stefanes NM, Neufeldt PD, Chiaradia-Delatorre LD, Nunes RJ, Santos-Silva MC. Aldehyde biphenyl chalcones induce immunogenic apoptotic-like cell death and are promising new safe compounds against a wide range of hematologic cancers. Future Med. Chem. 2020; 12(8):673–688.
Perondi DM, Jacques AV, Stefanes NM, Maioral MF, Sens L, Pacheco LA, Cury NM, et al. A novel thiosemicarbazone as a promising effective and selective compound for acute leukemia. Anticancer Drugs. 2019; 30(8):p 828-837.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Argenta DF, Dotto MER, Santos-Silva MC, et al. PEO-chitosan nanofibers containing carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanoparticles loaded with pyrazoline for skin cancer treatment. Eur. Polym. J. 2019; 119:335-343.
Rengifo AFC, Stefanes NM, Toigo J, Mendes C, Santos-Silva MC, Nunes RJ, Parize AL, et al. A new and efficient carboxymethyl-hexanoyl chitosan/dodecyl sulfate nanocarrier for a pyrazoline with antileukemic activity. Mater. Sci. Eng. C [Internet]. 2019; 105:110051.
Maioral MF, Stefanes NM, Bigolin A, Zatelli GA, Philippus AC, Falkenberg MB, Santos-Silva MC. Miconidine acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cells. Invest. New Drugs. 2019; 37:912–922.
Srefanes NM, Toigo J, Maioral MF, Jacques AV, Chiaradia-Delatorre LD, Perondi DM, Ribeiro AAB, et al. Synthesis of novel pyrazoline derivatives and the evaluation of death mechanisms involved in their antileukemic activity. Bioorg. Med. Chem. 2019; 27(2):375-382.
Maioral MF, Bodack CN, Stefanes NM, Bigolin A, Mascarello A, Chiaradia-Delatorre LD, Yunes RA, et al. Cytotoxic effect of a novel naphthylchalcone against multiple cancer cells focusing on hematologic malignancies. Biochim. 2017; 140:48-57.
You can view some of Dr Natália’s work below and links to her professional profile below.
Research Gate: https://www.researchgate.net/profile/Natalia-Stephanes
Linkedin: https://www.linkedin.com/in/nataliamarceli/
In this article, we will discuss the use of Pantoprazole in the morning and Famotidine at night. We will also discuss the potential benefits and risks of this combination.
Can you take Pantoprazole in the morning and Famotidine at night?
Yes, you can take Pantoprazole in the morning and Famotidine at night. Both Pantoprazole and Famotidine are used to manage acid reflux, but they belong to different drug classes and work differently (1,2).
Pantoprazole is a Proton Pump Inhibitor (PPI), and it works by blocking the proton pump in your stomach lining (1). This pump is the powerhouse behind the production of stomach acid.
By doing this, Pantoprazole significantly reduces the production of stomach acid, providing lasting relief. It’s usually taken in the morning on an empty stomach because this is when the proton pump is most active (1).
On the other hand, Famotidine is an H2 blocker (2). It targets histamine-2 receptors in the stomach lining, which are involved in acid production. By blocking these receptors, Famotidine reduces the amount of acid produced in the stomach (2).
It’s perfectly normal for some individuals to require more than just one acid reducer to effectively manage acid reflux, and Pantoprazole and Famotidine are two distinct options for achieving this relief.
Potential benefits of taking Pantoprazole in the morning and Famotidine at night
Taking Pantoprazole in the morning and Famotidine at night offers several potential benefits for managing acidity. When you take Pantoprazole before your first meal of the day, it sets the stage to effectively control stomach acid.
The key here is that an empty stomach provides an ideal environment for the medication to be absorbed properly. By inhibiting the proton pump responsible for acid production, Pantoprazole can prevent acid levels from going through the roof when food enters your stomach (1).
On the hand, taking Famotidine at night can offer multiple benefits. By administering Famotidine before your evening meal, you create a protective shield against nighttime acid reflux (3,4).
It can also be taken at bedtime which reduces stomach acid production precisely when you’re most vulnerable to acid-related discomfort – when lying down to sleep (3,4).
Acid reflux at night can be particularly bothersome, as the acid can flow back into your esophagus, causing irritation and discomfort. Famotidine at night helps prevent this by reducing the amount of acid in your stomach as you sleep (3,4).
This approach not only provides more relief from nighttime acidity but also promotes more restful sleep, as you won’t be awakened by acid reflux symptoms. This way, the concomitant use of these medications can be useful in providing comprehensive relief from the symptoms of acid reflux.
Potential risks of taking Pantoprazole in the morning and Famotidine at night
Taking Pantoprazole in the morning and Famotidine at night as separate medications is generally considered safe and does not pose any known risks in terms of drug interactions.
These two medications work differently to reduce stomach acid production, and there is no significant evidence to suggest that their combined use leads to adverse effects or interactions.
It’s important to note that, like any medications, both Pantoprazole and Famotidine can have potential side effects. However, these side effects are usually related to individual responses to each medication and are not typically exacerbated when taken separately (1,2).
People may experience side effects such as headache, nausea, diarrhoea, or dizziness, but these are usually mild and temporary (1,2).
However, make sure you’re not allergic to any of these medications. If you develop signs of an allergic reaction after taking either one of these meds, immediately seek medical attention.
Conclusion
In this article, we have discussed the potential risks and benefits of taking Pantoprazole in the morning and Famotidine at night. We have also discussed that these meds are not known to interact with one another and can be taken safely on the same day.
Was this helpful?
References
1.-
Bernshteyn MA, Masood U. Pantoprazole. 2023 Jul 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 29763120. https://www.ncbi.nlm.nih.gov/books/NBK499945
2.-
Nguyen K, Dersnah GD, Ahlawat R. Famotidine. 2022 Jul 11. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 30521199. https://www.ncbi.nlm.nih.gov/books/NBK534778
3.-
Mann SG, Murakami A, McCarroll K, Rao AN, Cottrell J, Mehentee J, Morton R. Low dose famotidine in the prevention of sleep disturbance caused by heartburn after an evening meal. Aliment Pharmacol Ther. 1995 Aug;9(4):395-401. doi: 10.1111/j.1365-2036.1995.tb00397.x. PMID: 8527615. https://pubmed.ncbi.nlm.nih.gov/8527615/
4.-
Savarino V, Picciotto A, Magnolia MR, Scalabrini P, Mela GS, Celle G. Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. J Clin Pharmacol. 1987 Oct;27(10):790-3. doi: 10.1002/j.1552-4604.1987.tb02998.x. PMID: 2892864. https://pubmed.ncbi.nlm.nih.gov/2892864/
